The FDA will hold an advisory committee meeting in September to review Grail’s controversial cancer test after it failed to meet the primary endpoint in a large, randomized UK trial. The upcoming review sets the stage for another expert-driven assessment of the evidence base supporting early detection claims. Grail’s test has already been at the center of regulatory and scientific debate, with the failed endpoint raising questions about clinical benefit. The adcomm process is expected to examine trial design, endpoint interpretation, and whether the dataset supports the claimed performance. For the broader sector, the meeting signals how regulators continue to scrutinize multi-cancer early detection assays under randomized evidence standards rather than relying primarily on secondary metrics.